Genomic Landscape of Metastatic Urothelial Cancer in a Multicenter Cohort From Argentina.

Authors

Federico Cayol, Iván Macharashvili, Jessica Barochiner, María Pía Dominguez, Emiliano Menna, Pablo Jose Perez Mesa, Julieta Pandolfi, Omar Carranza, Rodrigo Sanchez, Andrea Marchioni, Geraldine Gueron, Luz Pena, Matias Cerini, Hernan Cutuli, Hernan Garcia Rivello, Gonzalo Taetti, Augusto Ferreyra Camacho

Published in

JCO global oncology. Volume 12. Issue 8. Pages e2600017. Epub Aug 27, 2026.

Abstract

The genomic landscape of advanced urothelial carcinoma (aUC) has enabled the development of targeted therapies; however, real-world data from Latin America remain limited.
We conducted a multicenter retrospective study including patients with aUC who underwent next-generation sequencing on tumor tissue. Molecular alterations were classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT).
A total of 107 patients were included. Overall, 68 patients (63.6%) harbored at least one potentially actionable molecular alteration. Among these, 34 patients (31.8%) exhibited ESCAT level I alterations, most commonly involving FGFR3 mutations/fusions and ERBB2 amplification.
A clinically meaningful proportion of Argentine patients with aUC harbor ESCAT level I actionable alterations, supporting the incorporation of routine genomic profiling into clinical practice.

PMID:
42659586
Bibliographic data and abstract were imported from PubMed on 28 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.